Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress
'We look forward to sharing more about the potential of our modifier gene therapy platform and the meaningful results we are seeing in the clinic during these two important meetings for the retina community,' said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. 'Ocugen remains on track to deliver on our commitment to file three Biologics License Applications (BLAs)/Marketing Authorization Applications (MAAs) in the next three years—potentially addressing significant unmet medical need for large patient populations through our gene-agnostic approach.'
The ARVO Annual Meeting is a premiere gathering for eye and vision scientists from across the globe, students, and those in affiliated fields to share the latest research findings and collaborate on innovative solutions. Retina World Congress brings together leading retina specialists from every continent to achieve a global scientific and clinical exchange in retinal health.
Ocugen's presence in Utah kicks off with the Company Showcase at Eyecelerator, presented by Dr. Huma Qamar, Chief Medical Officer at Ocugen, and continues through presentations and thought leadership engagement at ARVO.
Eyecelerator @ Park City 2025
Session: Retina—Gene Therapy and Novel Mechanisms of Action Showcase
Location: Grand Hyatt Deer Valley, Strawberry Ballroom, Park City, UT
Date: Friday, May 2, 2025
Time: 2:06 p.m. MDT
Presenter: Dr. Huma Qamar
ARVO
Exhibitor Education Forum
Two-Year Follow-Up of a Phase 1/2 Clinical Trial for the Safety and Efficacy of OCU400 Novel Modifier Gene Therapy for Retinitis Pigmentosa
Location: Exhibitor Floor, Section 1037
Date: Monday, May 5, 2025
Time: 2 p.m. MDT
Presenter: Benjamin Bakall, MD, Ph.D., Assistant Clinical Professor, University of Arizona, College of Medicine–Phoenix, and Director for Clinical Research, Director for The Inherited Retinal Disease and Visual Function Clinic, Associated Retina Consultants
Safety and Efficacy of OCU410ST: A Phase 1/2 Trial of a Novel Modifier Gene Therapy for Stargardt Disease (GARDian)
Location: Exhibitor Floor, Section 1037
Date: Tuesday, May 6, 2025
Time: 2 p.m. MDT
Presenter: Syed M. Shah, MD, FACS, Vice Chair for Research and Digital Medicine, Director of Retina Service at Gundersen Health System, La Crosse, Wisconsin
An Evaluation of the Safety and Efficacy of Novel Modifier Gene Therapy OCU410 for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Location: Exhibitor Floor, Section 1037
Date: Wednesday, May 7, 2025
Time: 2 p.m. MDT
Presenter: Neena Haider, Ph.D., Faculty Harvard Medical School and Founder, CEO, Shifa Precision
Paper Session
Preliminary Safety and Efficacy of OCU410 for Treatment of Geographic Atrophy: Phase 1/2 OCU410: The Age-related Macular Degeneration (ArMaDa) Study Update
Presentation Number: 3675
Session Number and Title: 358/AMD Clinical research II
Location: Ballroom J
Date: Tuesday, May 6, 2025
Time: 4:15 p.m. MDT
Presenter: Syed M. Shah, MD, FACS, Vice Chair for Research and Digital Medicine, Director of Retina Service at Gundersen Health System, La Crosse, Wisconsin
Poster Session
A0513: Safety and Efficacy of OCU410ST for the Treatment of Stargardt Disease: Phase 1/2 Study Update
Location: Hall A-E
Date: Thursday, May 8, 2025
Time: 2 p.m. MDT
Presenter: Ramiro Maldonado, MD, Duke Center for Ophthalmic Genetics, Duke Pediatric Retina, Adult vitreo-Retinal diseases
Dr. Qamar will represent Ocugen at Retina World Congress to share the Company presentation and serve alongside notable retinal surgeons and industry peers during a panel discussion.
Retina World Congress
Retina Unplugged
Inherited and Rare Retinal Diseases Session
Moderators: Rishi P. Singh, MD, FASRS and Kourous A. Rezaei, MD
Location: Grand Ballroom
Date: Thursday, May 8, 2025
Time: 10:35 am – 11:12 a.m. EDT
Ocugen is committed to bringing game-changing therapies to treat inherited retinal diseases as well as blindness diseases affecting millions to market and working even harder to provide access to patients globally.
About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient's lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995,including, but not limited to, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines,which are subject to risks and uncertainties. We may, in some cases, use terms such as 'predicts,' 'believes,' 'potential,' 'proposed,' 'continue,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'intends,' 'may,' 'could,' 'might,' 'will,' 'should,' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities
Contact:
Tiffany Hamilton
AVP, Head of Communications
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Apple's India Production Milestone Could Cushion Earnings Against Tariff Impact
Tech giant Apple Inc (NASDAQ:AAPL) is one of many companies that could be hurt by tariffs placed on international markets for exporting items into America. To help combat the rising tariff rates, Apple has placed increased emphasis on diversification. Here's the diversification milestone the company recently reached. What Happened: Ahead of the highly anticipated launch of the iPhone 17, Apple has reached a milestone in production of all four models of the new phone in India. The company will be able to produce all versions of the upcoming phone, including professional versions. This marks the first time that all models will be made in India, according to a report from Bloomberg. Apple will produce the iPhone 17 at five factories in India, including two factories that recently opened. The increased production in India comes as Apple tries to lower its reliance on getting products imported from China. Apple has shifted the majority of its iPhone production to India from China for models specifically designed for the U.S. market. Indian conglomerate Tata Group is the owner of several of the plants in India, according to the report. Since April, Apple has exported $7.5 billion worth of iPhones from India, compared to $17 billion exported from India in the entire last fiscal year. Apple is also planning to use India to make the new iPhone 17e set for a 2026 release date, and the country could factor into the iPhone 18 production, according to the report. Read Also: Why It's Important: Constantly changing tariffs have left Apple with changing estimates on what the impact could be for the iPhone 17, with tariffs currently 50% on India and reciprocal tariffs on China paused until November, with a baseline of 10%. The iPhone and other electronics have been exempt from some tariffs by the Trump administration. Apple's current estimate is a $1.1 billion impact of tariffs for the current quarter. That figure could change depending on where rates on China and India stand and whether electronics are subject to the full tariff amount. Outside of producing items in China and India, Apple has also made efforts to win over the Trump administration through promises to invest more in American manufacturing. Apple CEO Tim Cook recently announced that the company would invest $600 billion to expand its U.S. operations. This move may have been made to secure exemptions on items imported from India. Apple is still using China to assemble iPhones set to be delivered to other countries. In 2021, China represented 99% of all global iPhone production. Last year, the figure fell to 81%. By 2027, China is expected to account for 50% of global iPhone production. By shifting production plans for U.S.-ready smartphones to India, Apple could enhance its diversification efforts and potentially lower its tariffs, given the likelihood that tariffs on smartphones from China will be higher than those from India in the coming months. Apple is likely to face tariff costs going forward, but the company's strategic shift to India production and the focus on winning over the Trump administration could help boost earnings and provide protection to the downside and worst-case scenarios that investors and analysts had predicted. AAPL Price Action: Apple stock is down 0.3% to $230.32 on Tuesday versus a 52-week trading range of $169.21 to $260.09. Apple stock is down 5.6% year-to-date in 2025. Read Next: Photo: Prathmesh T on UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Apple's India Production Milestone Could Cushion Earnings Against Tariff Impact originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
NBC News
an hour ago
- NBC News
Nasdaq tumbles as Jackson Hole jitters hit tech stocks
The Nasdaq and S&P 500 slid on Tuesday driven by tech stocks, as investors gear up for what Federal Reserve chair Jerome Powell will say about the path of interest rates at a key conference later in the week. The Nasdaq fell as megacaps lost, after having rallied for much of the year. Nvidia fell 3.5%, the biggest drop in nearly four months. The key event this week is the Fed's annual symposium at Jackson Hole, Wyoming, from Aug. 21-23, where Powell's comments will be scrutinized for any clues on the central bank's outlook on the economy and monetary policy. 'It seems like folks are hedging a little going into Jackson Hole, thinking Powell might be more hawkish than markets currently appreciate,' said James Cox, managing partner at Harris Financial Group. Interest rate futures point to a total of two rate cuts this year worth 25 basis points each, with the first expected in September, according to data compiled by LSEG. Some market participants also expressed some concerns about AI-related stocks after OpenAI's CEO Sam Altman said they are in a bubble in an interview with 'The Verge' late last week. The Dow Jones Industrial Average rose 10.45 points, roughly flat, to 44,922.27, the S&P 500 lost 37.78 points, or 0.59%, to 6,411.37 and the Nasdaq Composite lost 314.82 points, or 1.46%, to 21,314.95. Steve Sosnick, chief strategist at Interactive Brokers, said some investors are taking some profits from tech stocks and rotating into other sectors. '(This move) spills into the broader market because of those stocks' weight in major indices,' he added. Still, six of the S&P 500 sectors rose. Real estate led the pack, up 1.8%, helped by better-than-expected housing data. On the other hand, technology and communications services lost over 1.9% and 1.2%, respectively. A Reuters poll showed on Tuesday that the S&P 500 will end 2025 just below current near-record levels, at 6,300 points, reflecting tempered optimism amid ongoing concerns over the economic impact of President Donald Trump's global tariffs and uncertainty surrounding Fed rate cuts. The blue-chip Dow briefly hit a record high on Tuesday, aided by a rise in Home Depot's shares after the retailer kept its annual forecasts intact. Home Depot rose 3.17% despite missing quarterly results estimates, while rival home-improvement chain Lowe's also gained 2.18%. Earnings from Lowe's and big-box retailers Walmart and Target later this week are now in focus as investors await more insight on the health of the American consumer. 'Consumers are still not really spending at full speed ahead, they're a little bit cautious,' said Peter Cardillo, chief market economist at Spartan Capital Securities. 'They're waiting to see the full results of the tariffs' impact on the upcoming holiday sales in a couple of months from now.' Intel jumped roughly 7% after the chipmaker got a $2 billion capital injection from Japan's SoftBank Group. Palo Alto Networks rose 3.06% after the cybersecurity company forecast fiscal 2026 revenue and profit above estimates. Medtronic lost 3.13%, after the company said it would add two new directors to its board after Elliott Investment Management took a large stake in the medical-device maker. Advancing issues outnumbered decliners by a 1.06-to-1 ratio on the NYSE. There were 205 new highs and 62 new lows on the NYSE. The S&P 500 posted 13 new 52-week highs and one new low while the Nasdaq Composite recorded 56 new highs and 88 new lows.
Yahoo
an hour ago
- Yahoo
Why Rocket Lab (RKLB) Stock Is Falling Today
What Happened? Shares of aerospace and defense company Rocket Lab (NASDAQ:RKLB) fell 8.8% in the afternoon session after investors took some profits off the table as markets awaited signals on future monetary policy from the Federal Reserve's Jackson Hole symposium later in the week. The downturn in the market was largely attributed to a significant sell-off in megacap tech and chipmaker shares. Nvidia, Advanced Micro Devices (AMD), and Broadcom all saw notable drops, dragging down the VanEck Semiconductor ETF. Other major tech-related companies like Tesla, Meta Platforms, and Netflix were also under pressure. A key reason for this trend is that much of the recent market gains have been concentrated in the "AI trade," which includes these large technology and semiconductor companies. So this could also mean that some investors are locking in some gains ahead of more definitive feedback from the Fed. The shares closed the day at $40.91, down 9% from previous close. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Rocket Lab? Access our full analysis report here, it's free. What Is The Market Telling Us Rocket Lab's shares are extremely volatile and have had 74 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 7 days ago when the stock gained 4.9% on the news that an in-line inflation report fueled hopes for interest rate cuts and the U.S. and China agreed to extend their tariff truce. The Consumer Price Index (CPI), a key measure of inflation, came in largely as expected, holding steady at 2.7% year-over-year. This reading boosted investor optimism that the Federal Reserve will have room to lower interest rates at its next meeting, which could reduce borrowing costs for companies and consumers. Adding to the positive sentiment, the U.S. and China extended their tariff truce for another 90 days. This development alleviates concerns about renewed trade tensions, which is a significant relief for industrial companies reliant on global supply chains and international sales. Together, these events create a favorable outlook for economic growth, benefiting cyclical sectors like industrials. Rocket Lab is up 63.9% since the beginning of the year, but at $40.92 per share, it is still trading 20.4% below its 52-week high of $51.39 from July 2025. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
